BCRX - BIOCRYST PHARMACEUTICALS INC

QQQ $ 612.14 $ 1.56 (0.26 %)

DIA $ 470.45 $ 1.64 (0.35 %)

SPY $ 672.31 $ 2.95 (0.44 %)

TLT $ 89.45 $ -0.19 (-0.21 %)

GLD $ 367.77 $ 0.35 (0.1 %)

Previous Close

$ 7.09

Open

$ 7.03

Bid

$ 6.75 x 275

Ask

$ 7.19 x 1,000

Day's Range

$ 6.84 - $ 7.12

52 Week Range

$ 6.00 - $ 11.31

Volume

5,770,379

Average Volume

Market Cap

1.49B

Beta (5Y Monthly)

$ 0.88

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-04-2025	09-30-2025	10-Q
2	08-05-2025	06-30-2025	10-Q
3	05-06-2025	03-31-2025	10-Q
4	02-25-2025	12-31-2024	10-K
5	11-05-2024	09-30-2024	10-Q
6	08-06-2024	06-30-2024	10-Q
7	05-07-2024	03-31-2024	10-Q
8	02-27-2024	12-31-2023	10-K
9	11-08-2023	09-30-2023	10-Q
10	08-07-2023	06-30-2023	10-Q
11	05-08-2023	03-31-2023	10-Q
12	02-27-2023	12-31-2022	10-K
13	11-04-2022	09-30-2022	10-Q
14	08-05-2022	06-30-2022	10-Q
15	05-09-2022	03-31-2022	10-Q
16	02-28-2022	12-31-2021	10-K
17	11-04-2021	09-30-2021	10-Q
18	08-09-2021	06-30-2021	10-Q
19	05-07-2021	03-31-2021	10-Q
20	03-01-2021	12-31-2020	10-K
21	11-06-2020	09-30-2020	10-Q
22	08-10-2020	06-30-2020	10-Q
23	05-11-2020	03-31-2020	10-Q
24	03-13-2020	12-31-2019	10-K
25	11-08-2019	09-30-2019	10-Q
26	08-08-2019	06-30-2019	10-Q
27	05-09-2019	03-31-2019	10-Q
28	03-14-2019	12-31-2018	10-K
29	11-08-2018	09-30-2018	10-Q
30	08-09-2018	06-30-2018	10-Q
31	05-09-2018	03-31-2018	10-Q
32	03-12-2018	12-31-2017	10-K
33	11-08-2017	09-30-2017	10-Q
34	08-08-2017	06-30-2017	10-Q
35	05-08-2017	03-31-2017	10-Q
36	02-27-2017	12-31-2016	10-K
37	11-08-2016	09-30-2016	10-Q
38	08-08-2016	06-30-2016	10-Q
39	05-09-2016	03-31-2016	10-Q
40	02-26-2016	12-31-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

BioCryst Pharmaceuticals Reports That Orla...
11/06/2025 13:25:49

Findings highlight negative psychosocial impact of HAE attacks and resulting ED/hospital visits on pediatric patients and thei...

Citizens Maintains Market Outperform on Bi...
11/05/2025 13:09:34

Citizens analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:BCRX) with a Market Outperform and lowers the price tar...

Barclays Maintains Equal-Weight on BioCrys...
11/04/2025 13:59:53

Barclays analyst Gena Wang maintains BioCryst Pharma (NASDAQ:BCRX) with a Equal-Weight and lowers the price target from $11 ...

Needham Maintains Buy on BioCryst Pharma, ...
11/04/2025 10:41:41

Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and lowers the price target from $20 to $18.

top-stocks-with-earnings-this-week-joby-ionq-amd-and-more

Top Stocks With Earnings This Week: Joby, ...
11/03/2025 14:14:07

Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Fr...

BioCryst Pharma Raises FY2025 Sales Guidan...
11/03/2025 12:01:28

BioCryst Pharma (NASDAQ:BCRX) raises FY2025 sales outlook from $580.000 million-$600.000 million to $590.000 million-$600.000 m...

BioCryst Pharma Q3 Adj. EPS $0.16 Beats $0...
11/03/2025 12:00:54

BioCryst Pharma (NASDAQ:BCRX) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.04...

Earnings Scheduled For November 3, 2025
11/03/2025 11:11:31

BioCryst Pharmaceuticals To Present Four A...
10/23/2025 11:03:48

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts at the Annual Scient...

TD Cowen Reinstates Buy on BioCryst Pharma...
10/15/2025 14:15:07

TD Cowen analyst Stacy Ku reinstates BioCryst Pharma (NASDAQ:BCRX) with a Buy and announces $30 price target.

Cantor Fitzgerald Maintains Overweight on ...
10/15/2025 14:11:32

Cantor Fitzgerald analyst Steven Seedhouse maintains BioCryst Pharma (NASDAQ:BCRX) with a Overweight and raises the price ta...

JMP Securities Maintains Market Outperform...
10/15/2025 11:21:33

JMP Securities analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:BCRX) with a Market Outperform and raises the pri...

Needham Maintains Buy on BioCryst Pharma, ...
10/15/2025 10:00:17

Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and raises the price target from $17 to $20.

12 Health Care Stocks Moving In Tuesday's ...
10/14/2025 17:06:11

biocryst-says-astria-therapeutics-700-million-deal-gives-perfect-second-product-candidate

BioCryst Says Astria Therapeutics $700 Mil...
10/14/2025 16:20:52

BioCryst will acquire Astria Therapeutics for $700 million to expand its HAE portfolio with navenibart, aiming for double-digit...

Trading Halt: Halt status updated at 7:15:...
10/14/2025 11:15:04

BioCryst to Acquire Astria Therapeutics fo...
10/14/2025 11:02:17

Trading Halt: Halted at 6:55:00 a.m. ET - ...
10/14/2025 10:55:04

BioCryst Pharmaceuticals And Biocryst Irel...
10/01/2025 13:37:47

-SEC Filing

ionis-pharma-wins-fda-nod-for-first-rna-targeted-therapy-for-rare-genetic-swelling-disorder

Ionis Pharma Wins FDA Nod For First RNA-Ta...
08/21/2025 18:24:53

FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch pat...